Experimental Drugs for the Treatment of Hepatitis D.

Thumbnail
Name:
Sandmann and Cornberg.pdf
Size:
408.9Kb
Format:
PDF
Description:
Open Access article
Download
Cast your vote
 
Your vote was cast
Thank you for your feedback
Authors
Sandmann, Lisa
Cornberg, Markus
Issue Date
2021-04-16

Metadata
Show full item record
Abstract
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.
Citation
J Exp Pharmacol. 2020 Nov 16;12:503-515. doi: 10.2147/JEP.S273120.
Affiliation
CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.
Publisher
Dovepress
Journal
Journal of experimental pharmacology
URI
http://hdl.handle.net/10033/622896
DOI
10.2147/JEP.S235550
PubMed ID
33889032
Type
Review
Language
en
ISSN
1179-1454
Collections

The following license files are associated with this item:

  • Creative Commons
Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International